Danielle Brill

Q: How accurate are Danielle Brill's stock ratings?

About 51% of Danielle's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, measured by 13Foresight from historical prices.

Q: How is Danielle ranked?

Danielle Brill is ranked #1364 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Truist Financial

Wall Street Analyst

★★★☆☆

#1364

on 13Foresight · ranked by our own returns

50%

Success Rate

-0.6%

Average Return

48 of 96 calls profitable · -159.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 50% of Danielle Brill's ratings turned a profit when each position was held for 2 year — averaging -0.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

136 Buy 25 Hold 0 Sell

Danielle's Stock Coverage 37 ratings · 2026-11-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
BIIB Biogen	Oct 29, 2026	BUY	Strong Buy +6.6% avg upside 53 analysts	$260.00 2.59% Upside	+1.5%	·
IRON Disc Medicine	Oct 20, 2026	BUY	Strong Buy +23.4% avg upside 21 analysts	$115.00 42.18% Upside	+0.7%	·
WVE Wave Life Sciences	Oct 02, 2026	BUY	Strong Buy +443.6% avg upside 30 analysts	—	-17.2%	·
IMVT Immunovant	Sep 24, 2026	HOLD	Strong Buy +38.4% avg upside 25 analysts	—	+1.2%	·
RAPP Rapport Therapeutics, Inc.	Sep 23, 2026	BUY	Strong Buy +158.1% avg upside 15 analysts	—	-23.4%	·
VRTX Vertex Pharmaceuticals	Sep 23, 2026	BUY	Strong Buy -20.5% avg upside 62 analysts	—	+4.3%	·
MAZE Maze Therapeutics, Inc.	Sep 22, 2026	BUY	Strong Buy +102.8% avg upside 14 analysts	$64.00 103.24% Upside	+21.0%	·
ALNY Alnylam Pharma	Sep 18, 2026	BUY	Strong Buy +76.3% avg upside 53 analysts	—	-31.1%	·
CLYM Climb Bio	Sep 04, 2026	BUY	Strong Buy +120.9% avg upside 21 analysts	—	-33.7%	·
SLDB Solid Biosciences	Aug 21, 2026	BUY	Strong Buy +176.4% avg upside 26 analysts	$20.00 222.65% Upside	-26.5%	·
ARGX Argenx Se	Aug 18, 2026	BUY	Strong Buy -8.2% avg upside 48 analysts	$1095.00 22.54% Upside	-3.3%	·
UPB Upstream Bio, Inc.	Aug 12, 2026	BUY	Strong Buy +774.9% avg upside 9 analysts	$25.00 633.08% Upside	-59.8%	·
BBIO BridgeBio Pharma	Aug 12, 2026	BUY	Strong Buy +26.0% avg upside 36 analysts	$107.00 42.83% Upside	-6.6%	·
TECX Tectonic Therapeutic	Aug 10, 2026	BUY	Strong Buy +176.5% avg upside 24 analysts	$60.00 203.27% Upside	-35.4%	·
INSM Insmed	Aug 10, 2026	BUY	Strong Buy +51.3% avg upside 37 analysts	$195.00 73.25% Upside	-10.1%	·
PRAX Praxis Precision Medicines	Aug 07, 2026	BUY	Strong Buy +99.2% avg upside 25 analysts	$616.00 115.35% Upside	-9.0%	·
DNTH Dianthus Therapeutics	Aug 06, 2026	BUY	Strong Buy +23.4% avg upside 32 analysts	$128.00 55.39% Upside	-16.5%	·
PVLA Palvella Therapeutics	Aug 05, 2026	BUY	Strong Buy +17.8% avg upside 28 analysts	$207.00 41.71% Upside	-1.6%	·
HRMY Harmony Biosciences Holdings	Aug 05, 2026	HOLD	Strong Buy +27.3% avg upside 14 analysts	$34.00 12.28% Downside	-11.7%	·
NBIX Neurocrine	Aug 03, 2026	BUY	Strong Buy +27.3% avg upside 37 analysts	$213.00 45.82% Upside	+1.9%	·
QURE uniQure	Dec 10, 2024	BUY	Strong Buy +121.1% avg upside 30 analysts	$9.11 63.36% Downside	+55.6%	·
RGNX RegenXBio	Nov 18, 2024	BUY	Strong Buy +389.7% avg upside 25 analysts	$18.00 150.05% Upside	-24.7%	·
AGIO Agios Pharma	Oct 10, 2024	BUY	Strong Buy +99.0% avg upside 30 analysts	$51.00 67.01% Upside	-23.9%	·
PTCT PTC Therapeutics	Oct 10, 2024	HOLD	Buy +35.4% avg upside 29 analysts	—	+68.1%	·
SRPT Sarepta Therapeutics	Oct 10, 2024	BUY	Buy +223.8% avg upside 50 analysts	$150.00 705.54% Upside	-85.4%	·
ACAD ACADIA Pharmaceuticals	Oct 10, 2024	HOLD	Strong Buy +71.5% avg upside 43 analysts	—	+35.9%	·
BMRN BioMarin Pharmaceutical	Oct 10, 2024	BUY	Strong Buy +63.6% avg upside 52 analysts	$79.00 35.03% Upside	-21.6%	·
DNLI Denali Therapeutics	Oct 10, 2024	HOLD	Strong Buy +104.7% avg upside 24 analysts	—	-24.4%	·
XENE Xenon	Oct 10, 2024	BUY	Strong Buy +53.0% avg upside 28 analysts	$50.00 33.67% Upside	-9.8%	·
KYNB Kyntra Bio	Jun 26, 2023	HOLD	Buy +615.8% avg upside 17 analysts	—	-92.2%	·
PASG Passage Bio	May 16, 2022	BUY	Buy +407.3% avg upside 14 analysts	$10.00 189.81% Upside	-20.7%	·
VERX Vertex	Jun 30, 2021	HOLD	Buy +117.1% avg upside 24 analysts	—	-11.1%	·
KROS Keros Therapeutics	May 27, 2020	BUY	Strong Buy +116.6% avg upside 21 analysts	$45.00 307.69% Upside	+23.7%	·
ALKS Alkermes	Feb 13, 2020	HOLD	Buy -3.4% avg upside 34 analysts	—	+31.4%	·
AXSM Axsome Therapeutics	Dec 16, 2019	BUY	Strong Buy +63.9% avg upside 30 analysts	$125.00 13.50% Downside	-58.0%	·
CBIO Crescent Biopharma	Nov 07, 2019	HOLD	Strong Buy +73.7% avg upside 17 analysts	$5.00 62.94% Downside	·	·
GILD Gilead Sciences	Jul 26, 2016	HOLD	Strong Buy -27.3% avg upside 66 analysts	—	+2.0%	·

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Danielle Brill — Frequently Asked Questions

How accurate are Danielle Brill's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Danielle's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, or -155.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Danielle ranked on 13Foresight?

Danielle Brill is currently ranked #1364 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Danielle cover?

Danielle most recently has ratings on BIIB, IRON, WVE, IMVT, RAPP, VRTX, MAZE, ALNY, CLYM, SLDB, ARGX, UPB and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Danielle Brill

Rating Distribution

Welcome to 13Foresight!